Triple Epidemic: Pandemic Fatigue and Misinformation as Possible Causes

The “Triple Epidemic” seems to have peaked, but what is it, and what should every industry, health system, and other companies do to mitigate the damage the triple epidemic continues to cause? What should these institutions do to prevent another one? Did vaccine misinformation lead to the current triple epidemic? Did nurse burnout?Infection Control Today® (ICT®) spoke with Precision's Maureen Hennessey and Cynthia Miller for answers to these questions. Installment 1 of 3.

LEARN MORE

Triple Epidemic: Pandemic Fatigue and Misinformation as Possible Causes2023-02-22T08:23:33-05:00

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

October 2022 heralded another crisis for hospitals and physicians: the tripledemic. It likely won't be the last season for a potential infectious disease calamity, so every healthcare stakeholder must play a role in mitigating the damage. However, issues such as staffing, vaccine fatigue, misinformation, and operational challenges may inhibit successful interventions. Precision's Maureen Hennessey and Cynthia Miller argue for the need to create a wholistic pandemic strategy that align's with the Quintuple Aim and supports the five aims: care-team well being, better patient care, healthier people, affordability, and health equity.

LEARN MORE

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim2023-02-21T10:27:39-05:00

De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions

HEOR data can help to close knowledge gaps and uncertainties that payers may possess when making decisions involving access and reimbursement. Precision's Jacquelyn Chou, Alexandria Portelli and Andrew Cournoyer discuss important steps in prelaunch HEOR planning to support a successful market launch.

LEARN MORE

De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions2023-02-20T21:28:58-05:00

Collaboration is Needed Among Stakeholders for Genetic Tests to be Beneficial

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

LEARN MORE

Collaboration is Needed Among Stakeholders for Genetic Tests to be Beneficial2023-01-19T09:23:27-05:00

40 Under 40: Isabella Sergio

We're excited to announce that two of our Precision colleagues have been named to MM+M's 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.

LEARN MORE

40 Under 40: Isabella Sergio2023-02-20T21:32:45-05:00

Social Determinants of Health (SDOH): Threee Trends to Watch in 2023

The healthcare sector is hastening adoption of population health approaches, including initiatives to improve outcomes by closing health disparity gaps. Precision's Maureen Hennessey, Ph.D., Jorge Font, Dominic Galante, M.D., Kris Kang, and Cynthia Miller, M.D. identify three trends to watch in 2023 to tackle pernicious social determinants of health challenges.

LEARN MORE

Social Determinants of Health (SDOH): Threee Trends to Watch in 20232023-01-19T06:47:41-05:00

Early Access vs. Proven Efficacy: FDA’s Accelerated Approval Process

As Congress moves to improve the accelerated approval process through the Accelerated Approval Integrity Act, we must understand its history and ways to mitigate unnecessary spending while maintaining access to innovative treatments. Precision's Cynthia Miller warns of potential unintended consequences as Congress moves to improve the accelerated approval process.

LEARN MORE

Early Access vs. Proven Efficacy: FDA’s Accelerated Approval Process2023-01-18T18:08:18-05:00

It Takes a Village: How Pharma Can Help Address the Mental Health and Substance Abuse Crisis

Changes in climate and extreme weather affect every stakeholder in the healthcare system, not just the physicians on the front lines. Precision's Cynthia Miller suggests we need a patient focused strategy to manage environmental risk and offers solutions that align with incentives.

LEARN MORE

It Takes a Village: How Pharma Can Help Address the Mental Health and Substance Abuse Crisis2022-11-09T18:26:08-05:00